![](https://endpts.com/wp-content/uploads/2021/12/Sek-Kathiresan-Verve-tile-scaled.jpg)
Sekar Kathiresan, Verve Therapeutics CEO
Updated: Verve plans first in-human base editing trial in the US after FDA lifts clinical hold
Verve Therapeutics is planning to begin an in-human base editing trial in the US in patients with heterozygous familial hypercholesterolemia (HeFH) after the FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.